

UNITED STATES PATENT AND TRADEMARK OFFICE

'n

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,903	01/20/2006	David W. Morris	PP23369.0003/20366-034US1	3389
SS255 7590 10/30/2007 SAGRES DISCOVERY INC. INTELLECTUAL PROPERTY - R440 P.O. BOX 8097 EMERYVILLE, CA 94662-8097			EXAMINER	
			STRZELECKA, TERESA E	
			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			MAILDATE	DELIVER I MODE
		•	10/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	•			
	Application No.	Applicant(s)		
Notice to Comply	10/540,903	MORRIS ET AL	MORRIS ET AL.	
Notice to Comply	Examiner	Art Unit		
	Teresa E. Strzelecka	1637		
NOTICE TO COMPLY WITH REQUIREMEN NUCLEOTIDE SEQUENCE AND/OR AMING	ITS FOR PATENT APF O ACID SEQUENCE D	PLICATIONS CONTA ISCLOSURES	AINING	
Applicant must file the items indicated below within the avoid abandonment under 35 U.S.C. § 133 (extension	e time period set the Office ns of time may be obtained t	action to which the Notice under the provisions of 37	e is attached to 7 CFR 1.136(a)).	
The nucleotide and/or amino acid sequence disclosur for such a disclosure as set forth in 37 C.F.R. 1.821 -	re contained in this application 1.825 for the following reason	on does not comply with ton(s):	the requirements	
1. This application clearly fails to comply with the directed to the final rulemaking notice published a the effective filing date is on or after July 1, 1998, 1998) and 1211 OG 82 (June 23, 1998).	it 55 FR 18230 (May 1, 1990)), and 1114 OG 29 (Mav	15, 1990). If	
2. This application does not contain, as a separate required by 37 C.F.R. 1.821(c).	e part of the disclosure on pa	aper copy, a "Sequence I	₋isting" as	
3. A copy of the "Sequence Listing" in computer re 37 C.F.R. 1.821(e).	eadable form has not been s	submitted as required by		
4. A copy of the "Sequence Listing" in computer recomputer readable form does not comply with the attached copy of the marked -up "Raw Sequence	requirements of 37 C.F.R. 1	mitted. However, the con 1.822 and/or 1.823, as inc	ntent of the dicated on the	
5. The computer readable form that has been filed unreadable as indicated on the attached CRF Dist submitted as required by 37 C.F.R. 1.825(d).	d with this application has be kette Problem Report. A Su	een found to be damaged bstitute computer readab	d and/or le form must be	
6. The paper copy of the "Sequence Listing" is not as required by 37 C.F.R. 1.821(e).	t the same as the computer	readable from of the "Sec	quence Listing"	
7. Other:				
Applicant Must Provide: ☑ An initial or substitute computer readable form (CF)	RF) copy of the "Sequence L	.isting".		
igttize An initial or substitute paper copy of the "Sequenc specification.	e Listing", as well as an ame	endment directing its entr	y into the	
	mputer readable copies are .821(f) or 1.821(g) or 1.825(the same and, where ap b) or 1.825(d).	plicable, include	
For questions regarding compliance to these	requirements, please o	ontact:		
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-42	12			

PatentIn Software Program Support
Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER

ART UNIT PAPER

20071025

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa Strzelecka whose telephone number is (571) 272-0789. The examiner can normally be reached on Monday-Friday between 9:00 AM and 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (571) 272-0782. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Teresa Strzelecka Primary Examiner Art Unit 1637

Tensastnelectia 10/29/07